The National Health Surveillance Agency (Anvisa) determined, this Friday (3), the seizure and prohibition of the sale, distribution and use of counterfeit units of Deca-Durabolin and Sustanon. The measure, determined in the body’s resolution, was taken after a complaint by the company Aspen Pharma about the circulation, in the Brazilian market, of counterfeit units of medicines, on behalf of another manufacturer. According to Anvisa, the counterfeit units have the company Schering-Plough as the manufacturer on their labels, but this company had the drug registrations canceled in 2017. In this case, the units of these drugs marketed with the company name Schering-Plough, even if are presented as within the validity period, they are false, says the agency. Sustanon is indicated for the treatment of testosterone replacement in men with conditions associated with primary and secondary hypogonadism, both congenital and acquired, when testosterone deficiency is confirmed by clinical features and biochemical tests. Deca-Durabolin belongs to the group of drugs known as anabolic steroids. The product helps rebuild tissues that have become weak because of chronic illness or severe damage. Anvisa advises that the population purchase medication only in duly regulated establishments, always inside the complete package and ask for an invoice. In the case of these two drugs, the regular manufacturer is Aspen Pharma. “In case of identification of units of drugs suspected of being counterfeit, the population should not use the product and should contact Aspen Pharma to verify the authenticity of the product. of the Notivisa system”, recommends the agency.
Agência Brasil
Folha Nobre - Desde 2013 - ©